Featured News

Periodically, the FDA hosts workshops to help researchers understand exactly what the FDA will be looking for (aka “endpoints”) when evaluating the efficacy of a proposed drug.

Researchers at MassGeneral Hospital for Children have found substantial gut microbiome changes in the intestines of at-risk infants before celiac disease onset.

ZED1227, an experimental drug was found to be able to prevent intestinal damage in a preliminary trial of 163 adults with celiac disease.

The Celiac Disease Foundation is pleased to invite you to the FDA’s GREAT VI, Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics Workshop on Celiac Disease, on Thursday, July 22, 2021 at 9AM Eastern.

68 percent of survey participants indicated that celiac disease had a major/moderate impact on their dating life.

The overall prevalence of celiac disease was found to be 1.6% - a much greater percentage than the 1% that researchers have been approximating for years.

The Celiac Disease Foundation is proud to be selected as an Official Charity Partner in the 2021 TCS New York City Marathon and open the application process for our 2021 NYC Marathon Team Gluten-Free team! We are seeking five runners who are passionate and seriously committed to training, running, and fundraising to accelerate celiac disease research. Please complete the application to join our 2021 team by June 23, 2021, 6pm PST. Ready, set, go!

Cabinet Health, a verified gluten-free OTC medicine company, announced their partnership with the Celiac Disease Foundation in order to better support the needs of the celiac community.

Assure your diet is truly gluten-free with the only at-home test to self-monitor accidental gluten exposure, GlutenDetect. Today only, use the discount code CDF621GF and receive 12% off your GlutenDetect at-home urine and stool test kits!

A recent study published in JAMA Network, using two decades worth of dietary data, concluded that gluten consumption in people without celiac disease did not impair cognitive function.